Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 7.1 GBX 2.9% Market Closed
Market Cap: 338.4m GBX
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

AGY Price Targets Summary
Allergy Therapeutics PLC

Wall Street analysts forecast AGY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGY is 13.26 GBX with a low forecast of 13.13 GBX and a high forecast of 13.65 GBX.

AGY Lowest Forecast
Wall Street Target
13.13 GBX
85% Upside
AGY Average Forecast
Wall Street Target
13.26 GBX
87% Upside
AGY Highest Forecast
Wall Street Target
13.65 GBX
92% Upside
Lowest
Price Target
13.13 GBX
85% Upside
Average
Price Target
13.26 GBX
87% Upside
Highest
Price Target
13.65 GBX
92% Upside
Allergy Therapeutics PLC Competitors:
Price Targets
A
002821
Asymchem Laboratories Tianjin Co Ltd
5% Downside
600436
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
32% Upside
000538
Yunnan Baiyao Group Co Ltd
24% Upside
AXSM
Axsome Therapeutics Inc
71% Upside
A
002821
Asymchem Laboratories Tianjin Co Ltd
5% Downside
600436
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
32% Upside
000538
Yunnan Baiyao Group Co Ltd
24% Upside
AXSM
Axsome Therapeutics Inc
71% Upside
GS71
GSK plc
9% Upside
RAPP
Rapport Therapeutics Inc
332% Upside

Revenue
Forecast

Revenue Estimate
Allergy Therapeutics PLC

For the last 13 years the compound annual growth rate for Allergy Therapeutics PLC's revenue is 2%. The projected CAGR for the next 2 years is 20%.

2%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Allergy Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Allergy Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-64%
Average Miss
What are analyst estimates?

See Also

Summary
AGY intrinsic value, competitors valuation, and company profile.
DCF Valuation
AGY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AGY stock valuation using valuation multiples.
Wall Street Estimates
AGY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AGY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AGY's stock price target?
Price Target
13.26 GBX

According to Wall Street analysts, the average 1-year price target for AGY is 13.26 GBX with a low forecast of 13.13 GBX and a high forecast of 13.65 GBX.

What is Allergy Therapeutics PLC's Revenue forecast?
Projected CAGR
20%

For the last 13 years the compound annual growth rate for Allergy Therapeutics PLC's revenue is 2%. The projected CAGR for the next 2 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.